Table of Contents
Definition / general | Essential features | Newborn screening (NBS) | History | Current status in the U.S. | Disorders included | Addition of disorders to the NBS panel | Regulation | Monitoring | Methodologies | Potential confounding factors | Limitations | Management | Board review style question #1 | Board review style answer #1 | Board review style question #2 | Board review style answer #2Cite this page: Oladipo O, Carayannopoulos MO. Newborn screening. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/chemistrynewbornscreening.html. Accessed December 24th, 2024.
Definition / general
- Newborn screening (NBS) is one of the most successful preventive health programs in the U.S. intended to identify clinically occult but potentially serious disorders that require immediate intervention
- The NBS program screens for some genetic, endocrine and metabolic disorders as well as hearing loss and critical congenital heart defects (CCHDs)
Essential features
- The goal of NBS is to detect the presence of treatable disorders early enough to provide an intervention and improve long term outcome
- NBS is performed in all states in the U.S.
- NBS consists of dried blood spot (DBS) screening, hearing loss screening and congenital heart disease screening
Newborn screening (NBS)
- Refers to a group of tests performed on newborns to identify early presymptomatic, treatable disorders, for which timely intervention is critical to improve long term outcome
- Intended to identify clinically occult but potentially serious disorders that require immediate intervention
- Considered a great public health achievement
- It is a state mandated public health program that begins with a heel poke for every baby before hospital discharge
- Parents have a right to opt out of NBS testing; each state has a procedure for the opt out process
- NBS is not a diagnostic test; it identifies babies at increased risk for certain genetic, metabolic or functional diseases
- The 6 pillars for a successful NBS program include education, testing, follow up, diagnosis, intervention or management, and evaluation (Mol Genet Metab 2001;74:64)
- The NBS program in the United States includes screening for
- Hearing loss
- Critical congenital heart defects (CCHD)
- Dried blood spot screening
- Testing for metabolic, hematologic, endocrine and other inheritable disorders
- Disorders included in the NBS panel are ones that can cause significant morbidity, mortality or intellectual disability without intervention
- Reference: Birth Defects Res 2020;112:350
History
- In 1963, Dr. Robert Guthrie developed a simple screening assay for the detection of phenylketonuria (PKU)
- NBS testing is performed from a dried blood spot
- DBS enables population screening due to ease of collection and the ability to mail the samples to off site, state centralized laboratories
- In the U.S., ~3,400 infants/year receive early intervention for diseases identified via NBS
- Reference: Annu Rev Nurs Res 2011;29:113
Current status in the U.S.
- In the U.S., ~4 million infants undergo NBS annually
- NBS is performed in all states and each state screens for at least 31 out of the 38 core or primary disorders
- Some states do not test for any of the secondary disorders while others test for up to 25 out of the 26 secondary disorders
- References: Pediatr Clin North Am 2019;66:369, NewSTEPs: Newborn Screening Status for All Disorders [Accessed 14 February 2024]
Disorders included
- Newborn screening primarily includes disorders listed on the recommended universal screening panel (RUSP)
- The RUSP is a list of disorders that the Secretary of the Department of Health and Human Services (HHS) recommends states include on their NBS panel
- 38 core conditions and 26 secondary conditions are included on the RUSP
- Disorders are categorized as
- Metabolic disorders
- Organic acid condition
- Fatty acid oxidation disorders
- Amino acid disorders
- Endocrine disorders
- Hemoglobin disorders
- Other disorders including lysosomal storage disorders, severe combined immunodeficiency (SCID), spinal muscular atrophy (SMA)
- Metabolic disorders
- Screening for hearing loss and CCHD is included in NBS and is performed in the hospital
- Most states screen for the majority of disorders on the RUSP and may also screen for additional disorders
- Full list of all disorders screened: HRSA: Recommended Uniform Screening Panel [Accessed 14 February 2024]
Addition of disorders to the NBS panel
- Criteria for inclusion of disorders
- To be included as a primary target condition in an NBS program, a condition should meet the following minimal criteria
- It can be identified at a time (24 - 48 hours after birth) at which it would not ordinarily be detected clinically
- A test with appropriate sensitivity and specificity is available for it
- There should be available treatment of the condition (Genet Med 2006;8:1S)
- To be included as a primary target condition in an NBS program, a condition should meet the following minimal criteria
- Each state is responsible for adding disorders to their NBS panel
- Most states have a public or expert advisory committee to support the process
- Advocacy groups may directly approach individual legislators to add specific disorders by statute
- Most states use the RUSP as a guide for what disorders should be included in the NBS panel
- Disorders included in the RUSP were chosen based on
- Evidence that supports the potential net benefit of screening
- Ability of states to screen for the disorder
- Availability of effective treatments
- New disorders are added to the RUSP following a formal process, requiring support from the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) and recommended by the HHS
- Process for adding a new disorder to the RUSP includes
- Submission of a nomination package to the committee
- Committee reviews the nomination package
- Committee votes on whether or not to send a nomination to evidence based review
- External group conducts an evidence based review
- Committee considers the evidence
- Committee votes on whether or not to recommend addition of the disorder to the RUSP
- Committee makes a recommendation
- HHS Secretary responds
- Reference: HRSA: Advisory Committee on Heritable Disorders in Newborns and Children [Accessed 14 February 2024]
Regulation
- NBS Saves Lives Act
- In 2008, U.S. Congress passed the original Newborn Screening Saves Lives Act (public law 110-204), which established national NBS guidelines and helped facilitate comprehensive NBS in every state; this act has been reauthorized since then, the latest being in 2021 (through FY2026) (Congress.gov: H.R.482 - Newborn Screening Saves Lives Reauthorization Act of 2021 [Accessed 23 February 2024])
- In the U.S., NBS is a state mandated public health program
- NBS programs are regulated and administered by the state, allowing each program to meet the state's specific needs
- Federal government also plays a role in administering and adding to the RUSP
Monitoring
- 8 quality indicators are used to evaluate the success of the NBS program (NewSTEPs: Quality Indicators [Accessed 14 February 2024])
- Percent or number of unsatisfactory specimens due to improper collection or transport
- Percent of DBS with at least 1 missing data field on the form
- Percent of newborns not receiving the NBS
- Percent of newborns that are lost to follow up
- Percent of infants with out of range results that require further testing
- Percent of missed cases
- Percent of confirmed positive cases
- Timeliness of the NBS activities
Methodologies
Laboratory method | Disorders |
Immunoassays | Congenital hypothyroidism Congenital adrenal hyperplasia Cystic fibrosis |
Electrophoresis | Hemoglobinopathies |
High performance liquid chromatography | Hemoglobinopathies |
Tandem mass spectrometry (MS/MS) | Amino acidemias Organic acidemias Fatty acid oxidation Urea cycle disorders Pompe disease Mucopolysaccharidosis, type I X linked adrenoleukodystrophy |
DNA based (RT-PCR, next generation sequencing) | Severe combined immunodeficiencies Spinal muscular atrophy Cystic fibrosis (second tier) |
Fluorimetry or colorimetry (digital microfluidics platform or plate based enzyme assay) | Pompe disease Mucopolysaccharidosis, type I |
Potential confounding factors
- Timing of sample collection: 24 - 48 hours; this is enough time for babies to feed, which is important for the detection of some metabolic disorders (e.g., phenylketonuria)
- DBS should arrive at the lab ideally within 24 hours of collection with a goal to have results by 5 days of life for critical disorders and 7 days for the remaining disorders (HRSA: Newborn Screening Timeliness Goals [Accessed 14 February 2024])
- Some states require a second screening within 7 - 14 days after the first sample collection to improve the sensitivity and specificity of screening
- Delay in receipt of the DBS by the measuring laboratory may lead to erroneous results
- Some metabolites are greatly affected by a variety of prenatal factors, including gestational age, birth weight and nutritional status, underlying illness, total parenteral nutrition and use of antibiotics (Pediatr Clin North Am 2019;66:369)
- Premature and sick infants are more likely to have a false positive / negative result on their initial screen due to immaturity of enzymes involved in metabolic pathways or clinical interventions received
- Blood transfusions: can give false results in hemoglobinopathy screening or enzyme screening; NBS should be carried out before transfusions or when the blood products will no longer interfere with testing
- Temperature and humidity of test cards, for example, can falsely lower biotinidase activity (HRSA: Newborn Screening Timeliness Goals [Accessed 14 February 2024])
- Maternal disorders, such as previously diagnosed metabolic disorders, may cause false positive results (B12 deficiency, hypothyroidism / hyperthyroidism)
- Medication use in pregnancy such as steroids or propylthiouracil may affect screening for congenital adrenal hyperplasia or hypothyroidism (Pediatr Clin North Am 2019;66:369)
Limitations
- Trade off to maximizing assay sensitivity is a large number of false positive results
- Depending on the disorder, it is estimated that > 90% of abnormal NBS results are false positives
- Increasing the number of disorders included in the NBS panel will increase the burden of false positive results
- Support for mandatory NBS could deteriorate if false positive results become excessive
- Reference: Pediatr Clin North Am 2019;66:369
Management
- A positive newborn screen sets off the management, which includes contacting the ordering facility and primary care physician
- State follow up team ensures that the family and specialists are notified
- Diagnostic testing is ordered by the specialist in a clinical laboratory followed by treatment if condition is confirmed
- Management includes emergency management and supportive / maintenance therapy; the urgency of follow up depends on the disorder
- Some disorders require dietary management to decrease the substrate in cases of enzyme deficiencies or to provide deficient metabolites; other modes of management include enzyme replacement, liver / stem cell transplant, gene therapy, toxin removal (hemodialysis / peritoneal dialysis)
- Management requires a multidisciplinary approach that often involves parents, nutritionists, geneticists, social workers, medical laboratory, school, community, therapists and psychologists
- The ACMG (American College of Medical Genetics and Genomics) and the National Coordinating Center for the Regional Genetics Networks have developed action (ACT) sheets as resources for healthcare providers on information regarding clinical decisions and next steps in diagnosis
- In addition, there are diagnostic algorithms for each disorder that list the confirmatory tests recommended to confirm the diagnosis (ACMG: ACT Sheets and Algorithms [Accessed 14 February 2024])
- NBS continues to expand; newer technologies for screening and confirmation of disorders and newer novel treatment options continue to push the expansion of NBS disorders
- Other parts of the world, like Europe, China, Latin America, Asia Pacific and the Middle East, have NBS programs in place with varying numbers of disorders and babies screened from country to country (International Society for Neonatal Screening (ISNS) [Accessed 14 February 2024])
- Reference: Indian J Pediatr 2021;88:679
Board review style question #1
Which of the following statements is true about the newborn screening program?
- The best time to collect heel prick blood spots from babies is immediately after birth
- Detects all inborn errors of metabolism
- It includes dried blood spot screening, hearing loss screening and congenital heart disease screening
- It is a federally mandated program in the United States
- It is estimated that ~20% of initial newborn screen results are false positives
Board review style answer #1
C. It includes dried blood spot screening, hearing loss screening and congenital heart disease screening. Answer D is incorrect because newborn screening is a state mandated program in the United States. Answer B is incorrect because it does not detect all inborn errors of metabolism. Answer A is incorrect because blood spots should be collected between 24 - 48 hours of birth after feeding has been established. Answer E is incorrect because false positives account for ~90% of cases; each positive result must be confirmed as soon as possible.
Comment Here
Reference: Newborn screening
Comment Here
Reference: Newborn screening
Board review style question #2
Which of the following is necessary for addition of a new disorder to the recommended universal screening panel (RUSP) for newborn screening?
- Disorders added to RUSP must be supported by patient advocacy groups
- Availability of a screening test with appropriate sensitivity and specificity
- The disorder has to be clinically present in the newborn period
- There must be a federal law passed mandating the addition of the disorder to the RUSP
- The screening test must be approved by the United States Food and Drug Administration (FDA)
Board review style answer #2
B. Availability of a screening test with appropriate sensitivity and specificity. This is one of the criteria for adding a disorder to the recommended universal screening panel (RUSP). Answer D is incorrect because no federal law is required for addition of disorders; the RUSP is a guide to states for newborn screening (NBS). Answer C is incorrect because the disorder does not have to present clinically in the newborn period. Answer A is incorrect because there is no requirement that disorders added to RUSP must be supported by patient advocacy groups. Answer E is incorrect because the screening test does not have to be FDA approved.
Comment Here
Reference: Newborn screening
Comment Here
Reference: Newborn screening